Glucomine Trio Tablet is a combination oral antidiabetic medication formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride (2 mg), a sulfonylurea that stimulates pancreatic beta cells to increase insulin secretion; Metformin (500 mg), a biguanide that decreases hepatic glucose production and enhances peripheral glucose uptake; and Voglibose (0.2 mg), an alpha-glucosidase inhibitor that delays carbohydrate absorption from the gastrointestinal tract, thereby reducing postprandial hyperglycemia. This synergistic combination targets multiple pathophysiological defects of type 2 diabetes, offering comprehensive blood glucose regulation. Glucomine Trio is indicated for patients inadequately controlled by diet, exercise, and monotherapy. It should be administered orally with meals to minimize gastrointestinal side effects, particularly those associated with Metformin and Voglibose. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and adjust dosage accordingly. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and, rarely, lactic acidosis. This medication should be used under strict medical supervision, with attention to contraindications such as type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component. Glucomine Trio Tablet provides an effective option for achieving optimal glycemic control in type 2 diabetes management.